Overview of the muscular dystrophies

Handbook of Clinical Neurology

Volumn 101, Issue , 2011, Pages 1-9

  Amato, Anthony A ^a   Griggs, Robert C ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOPSY; BOOK; GENE THERAPY; HUMAN; MUSCULAR DYSTROPHY;

BIOPSY; GENE THERAPY; HUMANS; MUSCULAR DYSTROPHIES;

EID: 79954551143     PISSN: 00729752     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-08-045031-5.00001-3     Document Type: Book

References (21)

1. Allamand V., Bidou L., Arakawa M., et al. Drug-induced readthrough of premature stop codons leads to the stabilization of laminin alpha2 chain mRNA in CMD myotubes. J Gene Med 2008, 10:217-224.
2. Amato A.A., Russell J. Neuromuscular Disease 2008, McGraw-Hill, New York.
3. Brooke M.H., Fenichel G.M., Griggs R.C., et al. Clinical investigation of Duchenne muscular dystrophy. Interesting results in a trial of prednisone. Arch Neurol 1987, 44:812-817.
4. Bushby K., Muntoni F., Bourke J.P. 107th ENMC International Workshop: The management of cardiac involvement in muscular dystrophy and myotonic dystrophy. Neuromuscul Disord 2003, 13:166-172.
5. Cheuk D.K., Wong V., Wraige E., et al. Surgery for scoliosis in Duchenne muscular dystrophy. Cochrane Database Syst Rev 2007, CD005375.
6. Fenichel G.M., Florence J.M., Pestronk A., et al. Long-term benefit from prednisone therapy in Duchenne muscular dystrophy. Neurology 1991, 41:1874-1877.
7. Fenichel G.M., Griggs R.C., Kissel J., et al. A randomized efficacy and safety trial of oxandrolone in the treatment of Duchenne dystrophy. Neurology 2001, 56:1075-1079.
8. Griggs R.C., Moxley R.T., Mendell J.R., et al. Duchenne dystrophy: randomized, controlled trial of prednisone (18 months) and azathioprine (12 months). Neurology 1993, 43:520-527.
9. Kissel J.T., McDermott M.P., Mendell J.R., et al. Randomized, double-blind, placebo-controlled trial of albuterol in facioscapulohumeral dystrophy. Neurology 2001, 57:1434-1440.
10. Kley R.A., Vorgerd M., Tarnopolsky M.A. Creatine for treating muscle disorders. Cochrane Database Syst Rev 2007, CD004760.
11. Manzur A., Kuntzer T., Pike M., et al. Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database Syst Rev 2008, CD003725.
12. Mendell J.R., Moxley R.T., Griggs R.C., et al. Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy. N Engl J Med 1989, 320:1592-1597.
13. Mendell J.R., Kissel J.T., Amato A.A., et al. Myoblast transfer in the treatment of Duchenne's muscular dystrophy. N Engl J Med 1995, 333:832-838.
14. Mercuri E., Bushby K., Ricci E., et al. Muscle MRI findings in patients with limb girdle muscular dystrophy with calpain 3 deficiency (LGMD2A) and early contractures. Neuromuscul Disord 2005, 15:164-171.
15. Moxley R.T., Aswal S., Pandya S., et al. Practice parameter: corticosteroid treatment of Duchenne dystrophy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 2005, 64:13-20.
16. Muntoni F., Wells D. Genetic treatments in muscular dystrophies. Curr Opin Neurol 2007, 20:590-594.
17. Norwood F., de Visser M., Eymard B., et al. EFNS guideline on diagnosis and management of limb girdle muscular dystrophies. Eur J Neurol 2007, 14:1305-1312.
18. Skura C.L., Fowler E.G., Wetzel G.T., et al. Albuterol increases lean body mass in ambulatory boys with Duchenne or Becker muscular dystrophy. Neurology 2008, 70:137-143.
19. Tarnopolsky M.A. Clinical use of creatine in neuromuscular and neurometabolic disorders. Subcell Biochem 2007, 46:183-204.
20. van Deutekom J.C., Janson A.A., Ginjaar I.B., et al. Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med 2007, 357:2677-2686.
21. Wagner K.R., Fleckenstein J.L., Amato A.A., et al. A phase I/II trial of MYO-029 in adult subjects with muscular dystrophy. Ann Neurol 2008, 63:561-571.